New Locum Dr. Ariana Raufi
Ariana Raufi, MD is a native of Rhode Island. She received both her undergraduate and medical degrees from the combined 8 year Program in Liberal Medical Education at Brown University. In college, she majored in Human Biology with a focus on chronic disease prevention. During medical school, she focused her efforts on pediatric advocacy and activism. She spent one year during medical school at Children’s Hospital Los Angeles working on research projects while always being on the lookout for famous celebs! Dr. Raufi completed her pediatric residency in Chicago at Northwestern / Lurie Children’s Hospital where she stayed as an attending physician in their emergency department. The bitter winters and lack of foliage, however, swept Dr. Raufi back to the Northeast and she couldn’t be more excited!
Dr. Raufi has received multiple grants for her work in pediatric advocacy and obesity prevention and presented at several conferences. Her research interests and publications include advocacy, childhood obesity prevention and lead poisoning prevention. She is licensed in Rhode Island, Massachusetts, and Illinois and is certified by the American Board of Pediatrics.
New Expectant Parent Information Nights
Milton Pediatrics is hosting New Expectant Parents’ Nights on the following dates:
Tuesday - March 19, 2019
Tuesday - May 7, 2019
Tuesday – July 9, 2019
You can stop by anytime during those hours.
You will learn about what to expect at the hospital, our new breastfeeding support program, office philosophies, policies, tour our office and have an opportunity to meet some of our staff members.
Light refreshments will be served.
Please R.S.V.P by calling 781-356-6200 press 0 and leave a message on the line.
We look forward to meeting you.
Thank you,
Your Care Team at Milton Pediatrics!
Lactation Support Program
Milton Pediatrics
2018 Seasonal Flu Vaccine
Seasonal Flu Vaccine is now available in our office, please call 781-356-6200 for your appointment.
Thank you,
Milton Pediatrics
New Live Calls
On Tuesday, May 1st Milton Pediatrics will be transitioning to a new phone system. Our nurses will now be answering live calls from a queue system and you will no longer need to leave a voicemail for a callback. The live calls will begin at 9a until 5 pm.
Between the hours of 7a-8a, we will have our call hour where there you will leave a message and one of our nurses will call back. Between the hours of 8a-9a, you will be connected to our after-hours answering service.
Flu and Other Vaccinations
For all of our patients planning to receive the flu (or any other) vaccination, it is strongly recommended that patients come to Milton Pediatrics for vaccination accompanied by another person, ideally a parent/guardian.
If patients under 18 years of age arrive to Milton Pediatrics for vaccination without a parent/guardian, this person will be called in order to receive permission to administer the vaccination.
In addition, if any patient of driving age arrives alone for vaccination he/she will be asked to remain an additional 15 minutes to be monitored for any adverse symptoms or reactions.
Transition to Partners eCare
We would like to thank you for your patience while we upgrade to Partners eCare, our new electronic medical record system.
Our staff has undergone extensive training and we have made every effort to ensure that there is minimal impact to you during this transition. This system is still new to us and we apologize for any inconvenience you may experience.
Our first priority, as always, is to deliver the highest quality care possible. If you have any questions about Partners eCare, or your experience during today’s visit, please let any staff member know and we will be happy to assist you.
Thank you – your help makes the difference.
Hyland’s Teething Tablets Recalled
The maker of Hyland’s Teething Tablets, previously removed from the market due to inconsistent levels of potentially toxic substances, has now issued a recall for all remaining packages. Please see further information here: https://www.fda.gov/Safety/Recalls/ucm552934.htm.
Worldwide Recall of EpiPen® Auto-Injector
Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan’s manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (FDA).
This recall is being conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of failure to activate the device due to a potential defect in a supplier component. The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis). Both reports are related to the single lot that was previously recalled. The incidence of the defect is extremely rare and testing and analysis across the potentially impacted lots has not identified any units with a defect. However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution.
The recalled product was manufactured by Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016. The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.
The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies.
U.S. Impacted Lots:
| Product/Dosage | NDC Number | Lot Number | Expiration Date |
|---|---|---|---|
| EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg | 49502-501-02 | 5GN767 | April 2017 |
| EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg | 49502-501-02 | 5GN773 | April 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 5GM631 | April 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 5GM640 | May 2017 |
| EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg | 49502-501-02 | 6GN215 | September 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM082 | September 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM072 | September 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM081 | September 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM088 | October 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM199 | October 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM091 | October 2017 |
| EpiPen 2-Pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM198 | October 2017 |
| EpiPen 2-pak® Auto-Injectors, 0.3 mg | 49502-500-02 | 6GM087 | October 2017 |
Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall. Patients, customers and distributors are being notified and should refer to Mylan.com/EpiPenRecall for updates on product return and replacement instructions. We are asking patients to keep their existing product until their replacement product can be secured.
Patients may receive either EpiPen Auto-Injector or the authorized generic for EpiPen Auto-Injector at the pharmacy as a replacement based on availability. The authorized generic has the exact same drug formulation, has the exact same operating instructions and is therapeutically equivalent to EpiPen Auto Injector, and may be substituted for EpiPen Auto Injector.
It is important that patients continue to carry their current EpiPen Auto-Injector until they receive a replacement device.
To return your product please contact Stericycle at 877-650-3494. If you have any additional questions regarding this recall, please contact Mylan Customer Relations at 800-796-9526 or customer.service@mylan.com.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
This voluntary recall is being conducted with the knowledge of FDA.
Epinephrine is the first-line treatment for a life-threatening allergic reaction (anaphylaxis) and access to this product is critical in the event of an emergency. Delays in epinephrine administration have been associated with negative health consequences.
More information about the risks and benefits of EpiPen® Auto-Injector can be found at EpiPen.com.
Please see the full Prescribing Information and Patient Information.
Phones and Systems Back up!
Dear Patients,
Our Phones and systems are now working. When calling the offices please use the contact phone numbers for the corresponding office. The temporary email used yesterday is no longer in service and it is not monitored please discontinue using this method to reach out to us.
Thank you all so much for your patience and understanding during yesterdays outage.
Milton Pediatrics.
Phone and Systems outage
We are experiencing phone and systems outages in our Braintree office.
Please call 617-724-0924 for any after hours questions, or concerns regarding your child/ren.
Please do not email us using the email we had stated earlier, that email is not monitored after hours.
Please call 911 with any life-threatening concerns.
We apologize for any inconvenience this may cause.
Office closed – Tuesday March 14, 2017
Due to the inclement weather, our office will be closed on Tuesday March 14, 2017.
Office Opening at 12:00pm- Monday , February 13, 2017
Due to the inclement weather, our office will be opening at noon on Monday February 13, 2017.
FLU CLINIC INFORMATION
We have opened up flu clinics for the 2016-2017 flu season. The Flu vaccine will be administered by appointment only Monday through Friday and some Saturdays throughout the flu season. Please call 781-356-6200 during regular business hours to schedule an appointment.
Thank you,
Milton Pediatrics!
FLU VACCINE 2016-2017
We have recently received our first shipment of flu vaccine for the 2016-2017 season.
Flu vaccines can be given when you bring your child in for routine care. We will also be administering the flu vaccine at nurse visits by appointment only Tuesday through Friday throughout the flu season. Please call the nurse’s line 781-356-6200 option 3 during regular business hours to schedule an appointment. Please call in the morning to arrange same day appointments; appointments for a later date can be arranged as well.
The Center for Disease Control and Prevention recommends that everyone 6 months of age and older get a seasonal flu vaccine. Vaccination is especially important for children younger than 5 years of age and children of any age with a long-term health condition like asthma, diabetes and heart disease. These children are at higher risk of serious flu complications.
Click the link below for additional information about the flu vaccine:
http://www.cdc.gov/flu/protect/vaccine/index.htm
We will not be offering the nasal spray version of the flu vaccine, FluMist, this year. The CDC has recommended against the administration of the FluMist this year due to poor efficacy the past few flu seasons. http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html Please be advised that occasionally throughout the season we may be may be temporarily out of some formulations of the vaccines. These supplies are replenished as we receive additional shipments from the state.
Please speak to our nursing staff if you have any questions about the flu vaccine.
CDC and FDA Recommendation: Voluntary Recall of PharmaTech Liquid Medication Products
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Congratulations Dr. McCullough!
Dr. McCullough and her husband Craig welcomed Addison McCullough on July 13, 2016.
CDC/FDA Information re: Colace (Docusate)
As of Monday, July 11, 2016, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are recommending that both children and adults stop using liquid docusate, a stool softener. Docusate is available by prescription and over-the-counter and may be known by its brand name Colace. Liquid docusate may be linked to a recent outbreak of a bacterial infection (B. cepacia complex), which the CDC and FDA are investigating.
Congratulations Dr. and Mrs. Robinson!
Dr. and Mrs. Robinson welcomed their first great-grandchild, Avery, on April 20, 2016.
FDA proposes limit on arsenic in infant rice cereals
The US Food and Drug Administration (FDA) announced today that it wants to reduce the amount of inorganic arsenic in infant rice cereal to protect children from possible developmental problems.
The FDA released draft guidance for the food industry that sets a limit or action level of 100 parts per billion (ppb) for inorganic arsenic in this ubiquitous baby food. The agency also encourages parents to feed their infants a variety of iron-fortified cereals, and not only iron-fortified rice.
Pregnant women should diversify their grain consumption as well, because recent studies have linked intake of relatively high levels of inorganic arsenic to adverse pregnancy outcomes, the agency said in a news release. In addition, fetal exposure to inorganic arsenic together with dietary exposure during infancy can “result in a child’s decreased performance on certain developmental tests that measure learning.”
However, “consumers can certainly eat rice as part of a well-balanced diet,” the agency stated in a question-and-answer article on its website.
Reducing arsenic levels in rice is especially important for infants, the agency said, because relative to body weight, their intake of rice — primarily through cereal — is roughly three times greater than that for adults.
“Our actions are driven by our duty to protect the public health and our careful analysis of the data and the emerging science,” said Susan Mayne, PhD, director of the FDA’s Center for Food Safety and Applied Nutrition, in the news release. “The proposed limit is a prudent and achievable step to reduce exposure to arsenic among infants.”
Cancer Risk Also Assessed
Good manufacturing practices, the agency said, can produce infant rice cereal that complies with the proposed arsenic limit. Most manufacturers are already close. Of 76 infant rice cereals recently tested by the FDA, 47% did not exceed the proposed limit of 100 ppb, and 78% were at or below 110 ppb. Nonrice foods for infants and toddlers, in contrast, tested well below 100 ppb.
The agency noted that inorganic arsenic found in rice cereal and other foods is not an additive or ingredient, but something naturally absorbed by all plants from water, soil, and air. Rice tends to absorb more arsenic than most. Unlike organic arsenic, inorganic arsenic is not bonded to carbon, and when found in food, it is the more toxic of the two forms.
As part of its risk assessment, the FDA mathematically modeled the incidence of lung and bladder cancer associated with consuming inorganic arsenic in rice and rice products. It estimated that this exposure causes an extra four cases of lung and bladder cancer over the lifetime for every 100,000 people in the United States, the agency said. “This estimate would account for far less than 1 percent of the nation’s lung and bladder cancer cases.”
The US Environmental Protection Agency, the National Institutes of Health, and the US Department of Agriculture reviewed the FDA’s risk assessment of inorganic arsenic, as did nongovernment experts.
Once the industry guidance regarding inorganic arsenic levels in infant rice cereal is published on the Federal Register, the FDA will accept public comments for 90 days.
More information on today’s announcement is available on the FDA website.